2025-02-06 match.asia APAC Pte Ltd HaiPress
SINGAPORE,Feb. 5,2025 -- match.asia,Southeast Asia's premier M&A platform,has launched match NAVI,its proprietary AI Agent that leverages cutting-edge technology to automate key aspects of the mergers and acquisitions (M&A) process. With a curated marketplace model and a success-fee-only structure,match.asia is revolutionizing how M&A is conducted across the region,currently connecting over 250 sellers with a global network of 1,000+ investors.
Initially,match NAVI addresses two major challenges in the M&A process: investor outreach and marketing material preparation.
"Our mission is to connect every seller and adviser on our platform with the best global buyers for their business,"said Patrick Linden,Co-Founder of match.asia. "With match NAVI,what used to take weeks—manually researching,identifying,and reaching out to a curated investor list—can now be accomplished in a fraction of the time,ensuring greater speed and precision."
The platform also utilizes AI to create high-quality M&A marketing materials,such as teasers and investment memorandums. "By leveraging advanced AI automation,we've significantly enhanced efficiency and quality,saving time and reducing costs while delivering better outcomes," added Marcus Yeung,Co-Founder of match.asia.
These innovations solidify match.asia's position as an industry leader,committed to making the M&A process better,more efficient,and accessible to a wider range of sellers,advisers,and investors.
For more information,visit www.match.asia.
About match.asia
match.asia is an AI-driven M&A platform that connects sellers,and buyers of Southeast Asian companies. By combining advanced AI with a marketplace model,match.asia simplifies and accelerates the M&A process,making it more cost-effective,efficient,and successful for all parties involved.
Cangxi County Holds 2026 New Year's Cultural Performance for the Public
The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement
©copyright 2009-2020 Singapore Info Map